FY2025 EPS Estimates for ELDN Decreased by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($1.23) per share for the year, down from their previous estimate of ($1.12). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same period last year, the firm earned ($1.00) EPS.

Separately, Guggenheim started coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Stock Performance

Eledon Pharmaceuticals stock opened at $3.41 on Wednesday. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54. The firm has a market cap of $204.20 million, a PE ratio of -1.70 and a beta of 0.80. The firm’s 50 day moving average price is $4.13 and its two-hundred day moving average price is $3.88.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several large investors have recently made changes to their positions in ELDN. Tower Research Capital LLC TRC raised its position in Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after acquiring an additional 6,412 shares in the last quarter. Alpine Global Management LLC acquired a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth $56,000. ADAR1 Capital Management LLC bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at $66,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at $76,000. Finally, Virtu Financial LLC acquired a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at $82,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).